IP Library Granted Patent US 9,074,182
Granted Patent B2
US 9,074,182 · App. 13/679,663 · Granted Jul 7, 2015

Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes

Inventors: Jane S. Lebkowski (Portola Valley, CA); Catherine Ann Priest (San Carlos, CA); Ross M. Okamura (Menlo Park, CA)
Assignee: Asterias Biotherapeutics, Inc.
C12N5/0607C12N5/0623C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,074,182
App. No.
13/679,663
Granted
Jul 7, 2015
Kind
B2
Abstract

The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.

Claims (10)

1. A method of reducing the number of cells co-expressing TRA-1-60 and EpCAM in a mixed population of cells comprising:

a) providing a mixed population of cells comprising the in vitro progeny of pPS cells, wherein the mixed population of cells comprises i) cells co-expressing TRA-1-60 and EpCAM, and ii) oligodendrocytes differentiated from the pPS cells;

b) contacting the mixed population of cells with one or more ligands that specifically bind to EpCAM expressed on cells of the mixed population of cells; and

c) separating the ligand bound EpCAM expressing cells from the rest of the mixed population of cells to thereby reduce the number of cells expressing TRA-1-60 in the mixed population of cells.

2. The method of claim 1 , wherein the ligand is an antibody.

3. The method of claim 1 , wherein the ligand is bound to a solid support.

4. The method of claim 3 , wherein the solid support is a bead.

5. The method of claim 4 , wherein the bead is a magnetic bead.

6. The method of claim 1 , wherein separating the ligand bound EpCAM expressing cells from the rest of the mixed population of cells is performed by applying an external force to the mixed population of cells.

7. The method of claim 6 , wherein the external force is provided by a magnetic field.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031620/0567 →
Continuity (3)
Continuation 12823739 · Jun 25, 2010
Provisional Application 61220418 · Jun 25, 2009
Related Publication 20130210109A1 · Aug 15, 2013